CD72 as a complementary B‐lineage marker for longitudinal measurable residual disease surveillance after CD19 CAR ‐T therapy in R/R B‐ ALL

Cytometry Part B - Clinical Cytometry · Published 2026-08-03 · DOI 10.1002/cyto.b.70057

Authors (9)

Man Chen, Jing Zhou, Wei Zhao, Jing Long, Minjing Fu, Xian Zhang, Yi Li, Gailing Zhang, Hui Wang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Chen, M., Zhou, J., Zhao, W., et al. (2026). CD72 as a complementary B‐lineage marker for longitudinal measurable residual disease surveillance after CD19 CAR ‐T therapy in R/R B‐ ALL. Cytometry Part B - Clinical Cytometry. https://doi.org/10.1002/cyto.b.70057

Related articles